HK Stock Market Move | INNOGEN-B (02591) rose more than 18% in early trading, and two contract manufacturing sites for the production of Isupatide injection have obtained PIC/S GMP certification.

INNOGEN-B(02591) rose over 18% in early trading, and as of the time of writing, it has increased by 10.23%, trading at HKD 7.815, with a transaction volume of HKD 23.282 million. In news, on August 3, Silvergate Pharmaceuticals announced that Guangzhou Silvergate Pharmaceutical Group Co., Ltd. has passed the compliance inspection according to the PIC/S GMP standards by the Brazilian National Health Surveillance Agency (ANVISA) for its two entrusted production sites in China, and has obtained the relevant GMP certificates. The announcement stated that obtaining the PIC/S GMP certificate indicates that the raw material and formulation manufacturing and quality management systems at the group's entrusted production sites are in compliance with PIC/S GMP standards. This will further expand the group's commercial production capacity for Supaglutide and promote the completion of drug registration and commercialization in PIC/S member countries.